RT Journal Article
SR Electronic
T1 Multi-Omic Profiling of Plasma Identify Biomarkers and Pathogenesis of COVID-19 in Children
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.04.21252876
DO 10.1101/2021.03.04.21252876
A1 Chong Wang
A1 Xufang Li
A1 Wanshan Ning
A1 Sitang Gong
A1 Fengxia Yang
A1 Chunxiao Fang
A1 Yu Gong
A1 Di Wu
A1 Muhan Huang
A1 Yujie Gou
A1 Shanshan Fu
A1 Yujie Ren
A1 Ruyi Yang
A1 Yang Qiu
A1 Yu Xue
A1 Yi Xu
A1 Xi Zhou
YR 2021
UL http://medrxiv.org/content/early/2021/03/06/2021.03.04.21252876.abstract
AB Although children usually develop less severe disease responding to COVID-19 than adults, little is known about the pathogenesis of COVID-19 in children. Herein, we conducted the plasma proteomic and metabolomic profiling of a cohort of COVID-19 pediatric patients with mild symptoms. Our data show that numerous proteins and metabolites involved in immune as well as anti-inflammatory processes were up-regulated on a larger scale in children than in adults. By developing a machine learning-based pipeline, we prioritized two sets of biomarker combinations, and identified 5 proteins and 5 metabolites as potential children-specific COVID-19 biomarkers. Further study showed that these identified metabolites not only inhibited the expression of pro-inflammatory factors, but also suppressed coronaviral replication, implying that these factors played key roles in protecting pediatric patients from both viral infection and infection-induced inflammation. Together, our study uncovered a protective mechanism responding to COVID-19 in children, and sheds light on potential therapies.Teaser Anti-inflammatory metabolites were highly elevated in the plasma of COVID-19 pediatric patients with mild symptoms.Competing Interest StatementThe authors have declared no competing interest.Clinical Trial21600Funding StatementThis work was supported by the Strategic Priority Research Program of CAS (XDB29010300 to X.Z.), the National Science and Technology Major Project (2018ZX10101004 to X.Z.), National Natural Science Foundation of China (81873964 to Y.Q., 31930021, 31970633 and 34671360 to Y.X., and 31670161 to X.Z.), Grant from the CAS Youth Innovation Promotion Association (2020332 to Y.Q.), the program for HUST Academic Frontier Youth Team (Y.X.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All work performed in this study was approved by the Guangzhou Women and Children's Medical Center Ethics Committee and Written informed consent was waived by the Ethics Commission of the designated hospital for emerging infectious diseases.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org) via the iProX partner repository with the project ID: IPX0002173000, IPX0002243000 and IPX0002673000.